{"created":"2025-06-02T06:48:45.766193+00:00","id":2000281,"links":{},"metadata":{"_buckets":{"deposit":"58488314-5b49-4d0b-a18a-cc335e8b2fe1"},"_deposit":{"created_by":4,"id":"2000281","owners":[4],"pid":{"revision_id":0,"type":"depid","value":"2000281"},"status":"published"},"_oai":{"id":"oai:hbg.repo.nii.ac.jp:02000281","sets":["267:894:1744782447232"]},"author_link":[],"item_10002_biblio_info_7":{"attribute_name":"bibliographic_information","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2025-03-10","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"2","bibliographicPageEnd":"20","bibliographicPageStart":"1","bibliographicVolumeNumber":"26","bibliographic_titles":[{"bibliographic_title":"看護学統合研究"}]}]},"item_10002_description_5":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"高齢者の固形癌，特に膵癌の生存期間の改善に，副作用の無い化学療法や免疫療法に関して，日本初の有用な製剤を再評価する必要性があることを指摘したい。\n  免疫療法について，ヒト型結核菌青山株の熱水抽出物SSM（Specific substance MARUYAMA）は，70歳男性のホジキン病Ⅱ期に14年以上治療した経験，および純系Wistar/Furth（W/Fu）ラットの全身型白血病モデルを使用した治療実験で効果を認めた。放線菌由来のUbenimex は66歳男性の濾胞性リンパ腫Ⅳ期Ａの治療に著効を示した。RNA 合成阻害作用を有するAclarubicin（ACR, 放線菌由来）による急性非リンパ性白血病に対する効果から，固形癌へ応用可能と考えた。抗寄生虫薬Ivermectin について，腫瘍幹細胞に対する作用に注目した。SSM, Ubenimex, およびACR は, 多くの臨床腫瘍医に注目されていない。安価で副作用のないSSM の作用は，高額な免疫チェックポイント阻害薬と同様の獲得免疫の原理のCD8陽性Ｔリンパ球の働きに依存するが，自然免疫の働きを併用する必要がある。ACR は作用機序から使用法を考える必要がある。\n Ivermectin は人体に無害なポリマーとの結合体を開発する必要がある。高齢者固形癌にはDNA 合成阻害を中心とする抗癌化学療法のあとにACR の使用を考え，また，血清α１酸性糖蛋白低値に誘導後，SSM とUbenimex の併用療法を試行したい。膵癌の治療は難治性の理由が，間質に存在する腫瘍免疫抑制細胞の存在が大きな要因と考えて，その対策を考える必要がある。","subitem_description_language":"ja","subitem_description_type":"Abstract"}]},"item_10002_publisher_8":{"attribute_name":"出版者","attribute_value_mlt":[{"subitem_publisher":"広島文化学園大学看護学部"}]},"item_10002_source_id_11":{"attribute_name":"item_10002_source_id_11","attribute_value_mlt":[{"subitem_source_identifier":"AA12869764","subitem_source_identifier_type":"NCID"}]},"item_10002_source_id_9":{"attribute_name":"item_10002_source_id_9","attribute_value_mlt":[{"subitem_source_identifier":"1346-0692","subitem_source_identifier_type":"ISSN"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"岡田,浩佑","creatorNameLang":"ja"}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2025-03-31"}],"displaytype":"detail","filename":"hbgn26-2_1-20.pdf","filesize":[{"value":"781.8 KB"}],"format":"application/pdf","licensetype":"license_note","mimetype":"application/pdf","url":{"label":"hbgn26-2_1-20.pdf","objectType":"fulltext","url":"https://hbg.repo.nii.ac.jp/record/2000281/files/hbgn26-2_1-20.pdf"},"version_id":"76d02cbb-fc26-4a84-a745-f5fd8f9bbd95"}]},"item_keyword":{"attribute_name":"キーワード","attribute_value_mlt":[{"subitem_subject":"高齢者","subitem_subject_scheme":"Other"},{"subitem_subject":"膵癌","subitem_subject_scheme":"Other"},{"subitem_subject":"免疫抑制細胞","subitem_subject_scheme":"Other"},{"subitem_subject":"SSM（丸山ワクチン)","subitem_subject_scheme":"Other"},{"subitem_subject":"ubenimex(ベスタチン)","subitem_subject_scheme":"Other"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"jpn"}]},"item_resource_type":{"attribute_name":"item_resource_type","attribute_value_mlt":[{"resourcetype":"departmental bulletin paper","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"高齢者の固形癌の生存期間延長のための戦略，特に最も難治性の膵癌について","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"高齢者の固形癌の生存期間延長のための戦略，特に最も難治性の膵癌について","subitem_title_language":"ja"}]},"item_type_id":"10002","owner":"4","path":["1744782447232"],"pubdate":{"attribute_name":"PubDate","attribute_value":"2025-03-31"},"publish_date":"2025-03-31","publish_status":"0","recid":"2000281","relation_version_is_last":true,"title":["高齢者の固形癌の生存期間延長のための戦略，特に最も難治性の膵癌について"],"weko_creator_id":"4","weko_shared_id":-1},"updated":"2025-06-02T06:48:55.587937+00:00"}